slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 219,661-219,690
Pages 10,126
Rows per page 30
Component
219,661-219,690 of 303,780
25
Includes a blackbox warning text block as a competitive/safety barrier context.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
26
The slide outlines a clinical trial methodology and the strategic positioning of the drug candidate.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
27
Equillium | Investor Presentation Deck | 39 slidesEquillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
29
The slide uses a four-column structure to explain the biological rationale, molecular nature, mechanism of action, and clinical status.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
30
Includes a heatmap showing gene expression profiles under different cytokine conditions.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
31
The slide uses a circular process diagram to show the mechanism of action and a bar chart to show efficacy.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
33
The slide outlines a sequential clinical trial process.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Loop · Why Now1 hit
34
Equillium | Investor Presentation Deck | 39 slidesEquillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
36
The slide uses a Gantt-style timeline to show the duration of IP protection for various therapeutic assets.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Team1 hit
38
The slide uses a table-like structure to present clinical trial milestones and financial runway.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
39
Equillium | Investor Presentation Deck | 39 slidesEquillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
01
The slide uses a high-quality stock photo to evoke an emotional connection to the company's mission.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
02
Erasca | Investor Presentation Deck | 56 slidesErasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
04
SAB stands for Scientific Advisory Board.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
05
The table uses a heatmap-style color coding where red indicates existing targeted therapy markets and teal indicates blue ocean opportunities.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
06
The diagram illustrates a biological signaling pathway with specific nodes highlighted as targets for the company's therapeutic approach.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
07
The slide uses a Gantt-style visualization for clinical trial stages.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
08
The slide uses a biological process diagram to map drug assets to specific protein targets.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
09
The slide uses a matrix structure to map indications to benchmarks, specific drug regimens, and trial names, with a footer detailing active clinical trial collaboration and supply agreements (CTCSAs).Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
10
The chart uses a stacked bar approach to represent US and European patient counts per clinical program.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
11
The slide combines a biological pathway diagram (left) with a quantitative market sizing table (right).Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
12
The kinome tree visualization (KINOMEscan) is a standard industry tool for demonstrating kinase selectivity.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
13
The slide combines a biological pathway diagram (mechanism of action) with a clinical trial summary table.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
14
Includes two waterfall plots comparing patient responses; source cited as Novartis materials.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
15
The slide highlights the poor efficacy of current SOC and suggests binimetinib as a superior alternative.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
16
Waterfall plot uses standard clinical trial terminology (PD, SD, PR). Comparison table highlights the study drug's performance against Dacarbazine and Binimetinib.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
17
The slide uses a before-and-after visual comparison to demonstrate clinical efficacy.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
18
Swimmer plot visualization of clinical trial data (Trial LXH254X2102).Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
19
The slide highlights consistent clinical activity across two study phases, culminating in a combined ORR of 33.3%.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
21
The diagram uses a tree structure to categorize patient outcomes (off treatment vs on treatment, further broken down by SD and PR).Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit